ライフサイエンスコーパス: Sandostatin

1 ion of the somatostatin analogue octreotide (Sandostatin).

2 inhibition of growth hormone secretion than sandostatin.

3 e essential secondary structural features of sandostatin.

4 analog has a 2.4 times longer half-life than sandostatin.

5 rat SSTR5 compared to somatostatin[1-14] and sandostatin.

6 mes weaker binding affinity for mSSTR2b than sandostatin.

7 d6 and for other highly bioactive analogs of sandostatin.

8 rSSTR5 receptor selectivities as compared to sandostatin.

9 (2)) related to somatostatin analogues (e.g. sandostatin) acting at somatostatin receptors, CTAP whic

10 of beta-VI turns and can be incorporated in sandostatin analogs maintaining the essential secondary

11 statin-like and opioid-like bioactivities of sandostatin analogs, the present investigation shows the

12 The metabolic stability of lanthionine-sandostatin and sandostatin have been studied in rat bra

13 proposed structures for the design of novel sandostatin-based conformationally restricted peptidomim

14 ected to refine the pharmacophore models for sandostatin bioactivities.

15 The structural modification of sandostatin by introducing a lanthionine bridge resulted

16 y diffraction investigations which show that sandostatin can adopt both the beta-sheet and the 3(10)

17 lic stability of lanthionine-sandostatin and sandostatin have been studied in rat brain homogenates.

18 bone, lung, or lymph nodes before and after Sandostatin LAR administration (P > 0.05).

19 2 mo, and the mean time gap between the last Sandostatin LAR injection and the second (68)Ga-DOTATATE

20 the branch units of Glu-PLGAs extracted from Sandostatin LAR range from 2 (i.e., linear) at the lower

21 receiving long-acting repeatable octreotide (Sandostatin LAR) were included in the study.

22 nching parameters of Glu-PLGA extracted from Sandostatin LAR, as well as Glu-PLGAs obtained from thre

23 values measured after the administration of Sandostatin LAR.

24 rmational analysis of a series of analogs of sandostatin (octreotide, D-Phe1-c[Cys2-Phe3-D-Trp4-Lys5-

25 ys7+ ++-Thr8-ol (disulfide bridged) known as sandostatin (or SMS 201-995 or octreotide) with both som

26 These results facilitate the design of new sandostatin peptidomimetics.

27 e-initiated PLGA (Glu-PLGA) has been used in Sandostatin(R) LAR Depot (octreotide acetate for injecta

28 ctide:glycolide (L:G) ratio of 55:45 used in Sandostatin(R) LAR.

29 This is the initial report on sandostatin showing that attempts to explain all NMR dat

30 hesis of the thioether bridged analog (1) of sandostatin (SMS 201,995) and several lanthionine hexa-,